GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof
AssigneesSinopep-Allsino Biopharmaceutical Co., Ltd., Hangzhou Sinopep-Allsino Pharmaceutical Technology Development Co., Ltd.
InventorsChengqing Zhao, Guoqiang Shi, Shunzi Li, Caidian Wang
Life of this patent
Estimating the term…
Abstract
The disclosure provides a GLP-1 agonist polypeptide compound having an amino acid sequence: H Xaa1EGTFTSDVSSYLE Xaa2QAA Xaa3EFIAWLVRGRG (SEQ ID NO: 1). The C-terminal amino acid of the polypeptide compound is a carboxyl or the carboxyl is amidated. Xaa1 and Xaa2 are the same or different; R1 is: a straight-chain or branched-chain alkyl containing 2-6 carbon atoms, R2 is: H or CH3, X is: O, S or N—CH3, in the formula, R1 and R2 alkyl is optionally substituted by 1-6 halogen atoms.
Claims2
A GLP-1 agonist polypeptide compound, having an amino acid sequence:
- H Xaa1EGTFTSDVSSYLE Xaa2QAA Xaa3EFIAWLVRGRG (SEQ ID NO:
- 1), wherein a C-terminal amino acid of the polypeptide compound is a carboxyl or the carboxyl is amidated;
- wherein:
- Xaa1 is:
- Xaa2 is:
- G,
- Xaa1 and Xaa2 are the same or different;
- R1 is:
- a straight-chain or branched-chain alkyl containing 2-6 carbon atoms,
- R2 is:
- H or CH3,
- X is:
- O, S or N—CH3,
- R1 is optionally substituted by 1-5 halogen atoms in the case of 2 carbon atoms and 1-6 halogen atoms in the case of 3-6 carbon atoms;
- R2 is optionally substituted by 1-3 halogen atoms when R2 is CH3;
- Xaa3 is:
- n is a natural number ranging from 12 to 20;
- and
- m is a natural number ranging from 0 to 3.
Dependencies are inferred from the claim text.